Yahoo Finance

Minerva Biotechnologies - Overcoming the Solid Tumor Barrier: MUC1*-Targeted CAR T bearing 1XX mutations overcomes exhaustion and enables killing of low antigen expressing ...

WALTHAM, Mass., June 02, 2025--(BUSINESS WIRE)--Minerva Biotechnologies published "Effective CAR T cell targeting of a MUC1 cleavage product" in the Journal for ...
Business Wire

Minerva Biotechnologies Gets FDA Approval of IND for a MUC1*-CAR-1XX with Increased Persistence and Ability to Kill Low Antigen Expressing Cells for Treatment of Solid Tumor ...

WALTHAM, Mass.--(BUSINESS WIRE)--Minerva Biotechnologies, a private company developing 1 st-in-human therapies for the treatment of solid tumor cancers, announced today that the FDA has approved their ...